Uremic Toxins pp 171-187 | Cite as

Uremic Dysmetabolism and Its Effect on Immunocompetent and Erythroid Cell Function

  • Tor-Erik Widerøe
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 223)


From numerous of publications it is evident that an immunodeficiency exists in end-stage renal failure (ESRF) patients. To give a strict definition of these defects is, however, difficult.


Chronic Renal Failure Uremic Patient Mixed Lymphocyte Culture Continuous Ambulatory Peritonal Dialysis Patient Hemodialysis Membrane 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R.J. Glassock, Nutrition, immunology, and renal disease, Kidney Int. 26;Suppl. 16:194 (1985).Google Scholar
  2. 2.
    G.J. Laundy, and B.A. Bradley, Immunoglobulin allotypes in patients in end-stage renal failure, J Immunogenetics 12:181 (1985).CrossRefGoogle Scholar
  3. 3.
    R.F. Gagnon, J. Shuster, M. Kaye, Auto-immunity in patients with end-stage renal disease maintained on hemodialysis and continuous ambulatory peritoneal dialysis, J Clin Lab Immunol. 11:155 (1983).PubMedGoogle Scholar
  4. 4.
    M.A. Watson, J.D. Briggs, A.A. Diamandopoulous, D.N.H. Hamilton and H.M. Dick, Endogenous cell-mediated immunity, blood transfusion and outcome of renal transplantation, Lancet. 1:1323 (1979).CrossRefGoogle Scholar
  5. 5.
    A.K. Cheung, and L.W. Henderson, Effects of complement activation by hemodialysis membranes. Am J Nephrol. 6: 81 (1986).PubMedCrossRefGoogle Scholar
  6. 6.
    D.A. Casciato, L.P. McAdam, J.D. Kopple, R. Bluestone, L.S. Goldberg, P.J. Clements, and B.W. Knutson, Immunologic abnormalities in hemodialysis patients; Improvement after Pyridoxin therapy, Nephron. 38:9 (1984).PubMedCrossRefGoogle Scholar
  7. 7.
    L.D. Antoniou, and R.J. Shalhoub, Zinc-induced enhance ment of lymphocyte function and viability in chronic uremia. Nephron. 40:13 (1985).CrossRefGoogle Scholar
  8. 8.
    K.S. Kleinman, and D.C. Zoschke, Suppression of human lymphocyte responses in chronic renal failure mediated by adherent cells: Analysis in serum-free media. J Lab Clin Med. 106:262 (1985).Google Scholar
  9. 9.
    T. Kunori, I. Feherman, O. Ringden, and E. Möller, In vitro characterization of immunological responseiveness, Nephron. 26:234 (1980).Google Scholar
  10. 10.
    J.E. Lortan, P. Kiepiela, H.M. Coovadia, and Y.K. Seedat, Suppressor cell assayed by numerical and functional tests in chronic renal failure, Kidney mt. 22:192 (1982).CrossRefGoogle Scholar
  11. 11.
    Y.G. Alevy, K.R. Mueller, and R.G. Slavin, Immune response in experimentally induced uremia. VI. Uremic macrophages are defective in their ability to present antigen to T cells. Clin Immunol and Immunopath. 29:433 (1983).CrossRefGoogle Scholar
  12. 12.
    B. Charpentier, P.H. Lang, B. Martin, J. Noury, D. Marthieu, and D. Fries, Depressed polymorphnuclear leucocyte functions associated with normal cytotoxic functions of T and nature Killer cells during chronic hemodialysis, Clin Nephrology. 19:288 (1983).Google Scholar
  13. 13.
    J. Nelson, D.J. Ormrod, and T.E. Miller, Host immune status in uremia. IV. Phagocytosis and inflammatory response in vivo. Kidney Int. 23:312 (1983).PubMedCrossRefGoogle Scholar
  14. 14.
    K. Osaki, H. Otsuka, K. Uomizu, R. Harada, Y. Otsuji, and S. Hashimoto, Monocyte-mediated mitogen responses of lymphocytes in uremic patients. Nephron. 34:87 (1983).PubMedCrossRefGoogle Scholar
  15. 15.
    J. Rubin, L.M. Lin, R. Lewis, J. Cruse, and J.D. Bower, Host defence mechanisms in contnuous ambulatory peritoneal dialysis. Clin Nephrology. 20:140 (1983).Google Scholar
  16. 16.
    M.D. Smith, G. Hardy, J.D. Williams, G.A. Coles, Suppressor cell numbers and activity in non-transfused renal dialysis patients. Clin Nephrology. 20:130 (1983).Google Scholar
  17. 17.
    Y.G. Alevy, R. Mueller, J.R. Anderson, P.S. Hutcheson, and R.G. Slavin, The role of monocytes and responder cells in suppression of antigen-specific T cell proliferation in chronic renal failure. Int Archs Allergy Appl Immun. 73:97 (1984).CrossRefGoogle Scholar
  18. 18.
    I. Jatoi, R.G. Slavin, and Y.G. Alevy, Immune response in experimental uremia. VII Uremic thymocytes amplify the response of control lymph node cells to alloantigens. Clin Immunol and Immunopath. 30:80 (1984).CrossRefGoogle Scholar
  19. 19.
    S. Mezzano, A.J. Pesce, V.E. Pollak, and J.G. Michael. Analysis of humoral and cellular factors that contribute to impaired immune responsiveness in experimental uremia. Nephron. 36:15 (1984).PubMedCrossRefGoogle Scholar
  20. 20.
    J. Raskova, J. Ghobrial, S. Shea, R. Eisinger, and K. Raska jr.. Suppressor cells in end-stage renal disease. Functional assays and monoclonal antibody analysis. Am J Med. 76:847 (1984).PubMedCrossRefGoogle Scholar
  21. 21.
    W.C. Waltzer, R.J. Bachvaroff, A.P. Raisbeck, B. Egelandsdal, C. Pullis, L. Shen, and F.T. Rapaport, Immunological monitoring in patients with end-stage renal disease. J Clin Immunol. 4:364 (1984).PubMedCrossRefGoogle Scholar
  22. 22.
    E. Langhoff, and J. Ladefoged, In vitro natural killer and killer cell functions in uremia. Int Archs Allergy Appl Immun. 78:218 (1985).CrossRefGoogle Scholar
  23. 23.
    E. Mirapeix, J. Montolin, C. Suarez, J. Lopez Pedret, and L. Revert, Defective radioresistant suppressor cell activity in hemodialysis patients. Nephron. 41:184 (1985).PubMedCrossRefGoogle Scholar
  24. 24.
    D. Donati, P. Cervini, O. Amatruda, L. Baratelli, D. Cassani, A. De Maio, G. Frattini, M. Martegani, and L. Gastaldi, Nutritional state and immune function in uremic patients on maintenance hemodialysis. Proc Int Symp on Immune and Metabolic Aspects of Therapeutic Blood Purification Systems, Trondheim 1985, ed. Smeby LL, Jørstad S, Widerøe T-E, Karger Basel, pp 303–309. (1986).Google Scholar
  25. 25.
    R.F. Gagnon, Delayed-type hypersensitivity skin reaction in the chronically uremic mouse: Influence of severity and duration of uremia on the development of response. Nephron. 43:16 U986).Google Scholar
  26. 26.
    P. Kurz, H. Köhler, S. Meuer, T. Hütteroth, and K-H Meyerzum Büschenfelde, Impaired cellular immune responses in chronic renal failure: Evidence of T cell defect, Kidney Int. 29:1209 (1986).PubMedCrossRefGoogle Scholar
  27. 27.
    W.D. Tsakolos, Th.C. Theoharides, E.D. Kendler, J. Goffinet, J.M. Dwyer, R.L. Whisler, and P.W. Askenase, Immune defects in chronic renal impairment: evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on hemodialysis, Clin Exp Immunol. 63:218 (1986).PubMedGoogle Scholar
  28. 28.
    I. Fehrman, O. Ringden, and J. Bergström, MLC-blocking factors in uremic sera, Clin Nephrol. 14:183 (1980).PubMedGoogle Scholar
  29. 29.
    J. Raskova, and K. Raska, Humoral inhibitors of the immune response in uremia. IV. Effects of serum and of isolated serum very low density lipoprotein from uremic rats on cellular immune reactions in vitro. Lab Invest. 45:410 (1981).PubMedGoogle Scholar
  30. 30.
    G. Delaporte, F. Gros, C. Jonsson, and J. Bergström, In vitro cytotoxic properties of plasma samples from uremic patients, Clin Nephrol. 17:247 (1982).PubMedGoogle Scholar
  31. 31.
    K. Kamata, M. Okubo, and M. Sada, Immuno-suppressive factors in uremic sera are composed of both dialyzable and non-dialyzable components, Clin Exp Immunol. 54:277 (1983)PubMedGoogle Scholar
  32. 32.
    P.K. Donnelly, B.K. Shenton, A.M. Alomran, D.M.A. Francis, G. Proud, and R.M.R. Taylor, N new mechanism of humoral immunosuppression in chronic renal failure and its importance to dialysis and transplantation, Proc Europ Dial Transpl Assoc. 20:297 (1983).Google Scholar
  33. 33.
    M. Rola-Pleszczynski, D. Bolduc, S. Forand, G.E. Plante, and S. St-Pierre, Cellular immune function in uremia: Altered cytotoxic and suppressor cell responses to an immunomodulating heptapeptide, Clin Immunol and Immuno- path. 28:177 (1984).CrossRefGoogle Scholar
  34. 34.
    P. Youing, J. Cledes, J.P. Herve, P. Miossec, and W.J.W. Morrow, Low-affinity E-rosette-blocking factor in hemo- dialysis-treated patients in chronic renal failure, Clin Immunol and Immunopath. 26:423 (1983).CrossRefGoogle Scholar
  35. 35.
    J.F. Mangan, C. Chikkappa, L. Bieler, W.B. Scharfman, and D.R. Parkinson, Regulation of human blood erythroid Burst-Forming-Unit (BFU-E) proliferation by FC receptors and monoclonal antibodies. Blood. 59:990 (1982).PubMedGoogle Scholar
  36. 36.
    S. Lampari, and S. Carozzi, T lymphocytes, monocytes and erythropoiesis disorders in chronic renal failure. Nephron. 39:211 (1985).CrossRefGoogle Scholar
  37. 37.
    K.G. Chandy, M. Pähl, N.D. Vaziri, and S. Gupa, Acute effects of dialysis on T lymphocytes in patients with end-stage renal disease, J Clin Lab Immunol. 17:119 (1985).PubMedGoogle Scholar
  38. 38.
    A.M. Badger, D.B. Bernard, B.A. Idelson, and S.R. Cooperband, Depressed spontaneous cellular cytotoxicity associated with normal or enhanced antibody-dependent cellular cytotoxicity in patients with chronic hemodialysis, Clin Exp Immunol. 45:563 (1981).Google Scholar
  39. 39.
    P. Jüngers, J.F. DeLagneaw, P. Prunet, and J. Crosnier, Vaccination against hepatitis B in hemodialysis centers, Adv Nephrol. 11:303 (1982).Google Scholar
  40. 40.
    H. Köhler, W. Arnold, G. Renschin, H.H. Dormeyer, and K.H. Meyerzum Buschenfelde, Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int. 25:124 (1984).PubMedCrossRefGoogle Scholar
  41. 41.
    F.G. Casio, G.S. Giebink, C. Le Than, and G. Schiffman, Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipiens. Kidney Int. 20: 254 (1981).CrossRefGoogle Scholar
  42. 42.
    R. Cappel, D. Beers, C. Liesnard, and M. Sratwa, Impaired humoral and cell-mediated immune responses in dialyzed patients after influenza vaccination, Nephron. 33:21 (1983).PubMedCrossRefGoogle Scholar
  43. 43.
    J. Nikoskelainen, M. Koskela, J. Forsström, A. Kasanen, and M. Leinonen, Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int. 28;672 (1985).PubMedCrossRefGoogle Scholar
  44. 44.
    D. Urbanitz, and H.G. Sieberth, Impaired phagocytic activity of human monocytes in respect to reduced antibacterial resistance in uremia, Clin Nephrol. 4:13 (1975).PubMedGoogle Scholar
  45. 45.
    G. Lahnborg, L. Berghem, T. Ahlgren, L-G Groth, G. Lundgren, and A. Tillegard, Reticuloendothelial function in human renal allograft recipients. Transplantation. 28: 111 (1979).PubMedCrossRefGoogle Scholar
  46. 46.
    T.M. Saba, Physiology and physiopathology of the reticuliendothelial system. Arch Intern Med. 126:1031 (1970).PubMedCrossRefGoogle Scholar
  47. 47.
    K.L. Rosenstreich, J.J. Farrar, and S. Dougherty, Absolute macrophage dependency of T lymphocyte activation by mitogens. J Immunol. 116:131 (1976).PubMedGoogle Scholar
  48. 48.
    J. Knop, Influence of various macrophage population on Con A induced T cell proliferation. Immunology 41:379 (1980).PubMedGoogle Scholar
  49. 49.
    S.A. Rosenberg, and P.E. Lipsky, The role of monocyte factors in the differentiation of Immunglobulin secreting cells from human peripheral blood B cells. J Immunol. 125:232 (1980).PubMedGoogle Scholar
  50. 50.
    F.G. Meyling, and T.A. Waldmann, Human B cell activation in vitro: augmentation and suppression by monocytes of the Immunglobulin production induced by various B cell stimulants. J Immunol. 126:529 (1981).Google Scholar
  51. 51.
    D. Metcalf, C.G. Begley, G.R. Johnson, N.A. Nicola, M.A. Vadas, A.F. Lopez, D.J. Williamson, G.G. Wong, S.C. Clark, and E.A. Wang, Biologic properties in vitro of a recombinant human granulocyte-macrophage colony- stimulating factor. Blood 67:37 (1986).PubMedGoogle Scholar
  52. 52.
    O. Bakke, T. Balstad, L.C. Smeby, S. Jørstad, and T-E. Widerøe, Mononuclear cells (monocytes (OK 141+), T. and Tg+ cells) during hemodialysis. Proc Int Symp on litoune and Metabolic Aspects of Therapeutic Blood Purification Systems, Trondheim 1985, ed. Smeby L.C, Jøirstad S, Widerøe T-E, Karger Basel, pp 105–111 (1986).Google Scholar
  53. 53.
    R. Korz, U. Loe Guitz, B. Brunner, and R. Heinz, Lymphocyte enzymes of DNA synthesis in chronic renal failure. Proc Eur Dial Transpl Assoc. 13:528 (1976).Google Scholar
  54. 54.
    R.A. Gutman, and A.T. Auang, Inhibitor, of marrow thymidine incorporation from sera of patients with uremia. Kidney Int. 18:715 (1980).PubMedCrossRefGoogle Scholar
  55. 55.
    E.N. Wardle, A study of the possible toxic metabolites of uremia in red cell metabolism. Acta Haematol. 43:129 (1970).PubMedCrossRefGoogle Scholar
  56. 56.
    M. Kurada, T. Asaka, Y.M. Tofuku, and R. Takeda, Serum antioxidant activity in uremic patients. Nephron. 41: 293 (1985).CrossRefGoogle Scholar
  57. 57.
    M. Taccone-Galluci, O. Giardini, R. Lubrano, U. Mazzarella, D. Bardino, S. Khashan, O. Mannarino, M. Elli, M. Cozzari, U. Bounteristiani, and C.U. Casciani, Red blood cell membrane lipid peroxidation in continuous ambulatory peritonal dialysis patients. Am J Nephrol. 6:92 (1986).CrossRefGoogle Scholar
  58. 58.
    S. Jørstad and K. E. Viken, Inhibitory effects of plasma from uraemic patients on human mononuclear phagocytes cultured in vitro. Acta Path Microbiol Scand Sect C 859:169 (1977).Google Scholar
  59. 59.
    S. Jørstad, and S. Kvaernes, Uraemic toxins of high molecular weight inhibiting human mononuclear phagocytes cultured in vitro. Acta Path Microbiol Scand Sect C 86: 221 (1978).Google Scholar
  60. 60.
    S. Jørstad, L.C. Smeby, T-E. Widerøe, and K.J. Berg, Transport of uremic toxius through conventional hemodialysis membranes. Clin Nephrol. 12:168 (1979).PubMedGoogle Scholar
  61. 61.
    L.K. Curtiss, and T.S. Edgington, Differential sensitivity of lymphocyte subpopulation to suppression by low density lipoprotein inhibitor, an immunoregulatory human serum low density lipoprotein. J Clin Invest. 63:193 (1979).PubMedCrossRefGoogle Scholar
  62. 62.
    D. Modai, J. Weissgarten, U. Shaked, S. Segal, A. Pik, and R. Fuchs, Levamisole circumvents inhibition of lymphocyte activation imposed by uremic serum. Nephron. 40:436 (1985).PubMedCrossRefGoogle Scholar
  63. 63.
    P.A. Peterson, P.E. Ervin, and J. Berggard, Differentiation of glomerular, tubular, and normal proteinuria: determinations of urinary excretion of ß2-microglobulin, albumin and total protein, J Clin Invest. 48:1189 (1969).PubMedCrossRefGoogle Scholar
  64. 64.
    R.E. Birch, M.W. Fanger, and G.M. Bernier, ß2-microglobulin enhances lymphocyte surface receptor expression for IgG. J Immunol. 122:997 (1979).PubMedGoogle Scholar
  65. 65.
    P.A. Keown, and B. Descamps, Improved renal graft survival after blood transfusion: a nonspesific erythrocyte mediated immunoregulatory process. Lancet 1:20 (1979).PubMedCrossRefGoogle Scholar
  66. 66.
    B.S. Bender, J.L. Curtis, J.E. Nagel, F.J. Chrest, E.S. Kraus, G.R. Briefel, and W.H. Adler, Analysis of immune status of hemodialyzed adults: association with prior transfusions. Kidney Int. 26:436 (1984).PubMedCrossRefGoogle Scholar
  67. 67.
    R.M. Hakim, D.T. Fearon, M. Lazarus, and C.S. Perzanowski, Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int. 26:194 (1984).PubMedCrossRefGoogle Scholar
  68. 68.
    A.K. Cheung, D.E. Chenoweth, D. Otsuka, and L.W. Henderson, Compartmental distribution of complement activation products in artificial kidneys. Kidney Int. 30:74 (1986).PubMedCrossRefGoogle Scholar
  69. 69.
    L. C. Smeby, S. Jørstad, T. Balstad, and T-E. Widerøe, Dialyzer generation and plasma clearance of activated complement during hemodialysis. Proc Int Symp on Immune and Metabolic Aspects of Therapeutic Blood Purification Systems. Trondheim 1985, ed. Smeby LC, Jørstad S, Widerøe T.E, Karger Basel, pp 303 (1986).Google Scholar
  70. 70.
    D.E. Chenoweth, and T.E. Hugli, Demonstration of specific Cc- receptor on intact human polymorphonuclear leucocytes. Proc Nath Acad Sci USA 75 (8), 3943 (1978).CrossRefGoogle Scholar
  71. 71.
    S.L. Lewis, D.E. Van Epps, and D.E. Chenoweth, C5a- receptor modulation on neutrophils and monocytes from chronic hemodialysis and peritoneal dialysis patients. Clin Nephrol. 26:37 (1986).PubMedGoogle Scholar
  72. 72.
    R.M. Hakim, J. Breillatt, J.M. Lazarus, and F.K. Port, Complement activation and hypersensitivity reactions to dialysis membranes. Engl j Med. 311:878 (1984).CrossRefGoogle Scholar
  73. 73.
    S. Stefoni, A.N. Costa, M.P. Scolar, L. Coli, G. Mosconi, A. Buscaroli, P. Boni, S. lannelli, T. D. Atena, G. Cianciolo, L. Bruni, and U. Bonomini, DNA-content and surface antigen characteristics of T-cell subsets in chronic dialysis patients. Proc Int Symp on Immune and Metabolic Aspects of Therapeutic Blood Purifcation Systems, Trondheim 1985, ed. Smeby LC, Jørstad S, Widerøe T-E, Karger Basel pp 168 (1986).Google Scholar
  74. 74.
    Y. Chida, S. Sakurai, and N. Yoshiyama, The effect of hemo dialysis on lymphocyte subsets during dialysis. Clin Nephrol. 25:159 (1986).PubMedGoogle Scholar
  75. 75.
    M. Bingel, G. Lonnemann, S. Shaldon, K.M. Koch, and C.A. Dinarello, Human interleucin-1 production during hemodialysis. Nephron. 43:161 (1986).PubMedCrossRefGoogle Scholar
  76. 76.
    J.E. Hefti, A. Blumberg, and H.R. Marti, Red cell survival and red cell enzymes in patients on continuous peritoneal dialysis (CAPD). Clin Nephrol. 19:232 (1983).PubMedGoogle Scholar
  77. 77.
    R. Lerner, B. Werner, H. Asaba, B. Ternstedt, and E. Elmqvist, Assessment of hemodialysis in regular hemodialysis patients by measuring carbon monoxide production rate. Clin Nephrol. 20:239 (1983).PubMedGoogle Scholar
  78. 78.
    C.R. Angle, M.S. Swanson, S.J. Stohs, and R.S. Markin, Abnormal erythrocyte pyrimidin nucleotides in uremic subjects. Nephron. 39:169 (1985).PubMedCrossRefGoogle Scholar
  79. 79.
    G. Goubeaud, H.W. Leber, H.H. Schott, and G. Schütterle, Middle molecules and haemoglobulin synthesis. Proc Europ Dial Transpl Assoc. 13:371 (1976).Google Scholar
  80. 80.
    R.A. Gutman, A.T. Huang, and N.S. Bouknight, Inhibitor of marrow thymidin incorporation from sera of patients with uremia. Kidney Int. 18:715 (1980).PubMedCrossRefGoogle Scholar
  81. 81.
    H.W. Radtke, A.B. Rege, M.B. LaMarche, and D. Bartos. Identification of spermine as an inhibitor of Erythro- poiesis in patients with chronic renal failure. Clin Invest. 67:1623 (1981).CrossRefGoogle Scholar
  82. 82.
    R.J.S. McGonigle, J.D. Wallin, R.K. Shadduck, and J.W. Fischer, Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 25:437 (1984).PubMedCrossRefGoogle Scholar
  83. 83.
    T.E. Widerøe, T. Sanengen, and S. Halvorsen, Erythropoietin and uremic toxicity during continuous ambulatory dialysis. Kidney Int. 24, Suppl 16, 208 (1983).Google Scholar
  84. 84.
    F. Delwiche, G.M. Segal, J.W. Eschbach, and J.W. Adamson, Hematopoietic inhibitors in chronic renal failure: lack of in vitro specificity. Kidney Int. 29:641 (1986).PubMedCrossRefGoogle Scholar
  85. 85.
    J.W. Fisher, Mechanism of the anemia of chronic renal failure. Nephron. 25:106 (1980).PubMedCrossRefGoogle Scholar
  86. 86.
    W. Fried, and A. Anagnoston, Extrarenal erythropoietin production. In: Kidney Hormones, ed. Fischer J.W. vol. II:pp 231 (Academic Press, London 1977).Google Scholar
  87. 87.
    J. Caro, and A.J. Erslev, Uremic inhibitors of erythropoiesis. Semin Nephrol. 5:128 (1985).PubMedGoogle Scholar
  88. 88.
    B.P. Spragg, D.P. Bentley, and G.A. Coles, Anaemia of chronic renal failure. Polyamines are not raised in uremic serum. Nephron. 38:65 (1984).PubMedCrossRefGoogle Scholar
  89. 89.
    D. Meytes, E. Bogin, A. Ma, P.P. Dukes, and S.G. Massry, Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 67:1263 (1981).PubMedCrossRefGoogle Scholar
  90. 90.
    F. Delwiche, M.J. Garrity, J.S. Powell, R.P. Robertson, and J.W. Adamson, High level of the circulating form of parathyreoid hormone do not inhibit in vitro erythropoiesis. J Lab Clin Med. 102:613 (1983).PubMedGoogle Scholar
  91. 91.
    J.B. Sherwood, and E. Goldwasser, A radioimmunoassay for erythropoietin. Blood 54:885 (1979).PubMedGoogle Scholar
  92. 92.
    P.M. Cotes, Immunoreactive erythropoietin in serum. I. Evidence of the validity of the assay method and the physiological relevance of estimates. Br J Hemat. 50:427 (1983).Google Scholar
  93. 93.
    M.C. Bordas, N.S. Serbource-Goguel, J.M. Feger, J.M. Maccario, J.M. Agneray, and G.M. Durand, Evaluation of the degree of desialynation of serum a--acid glucoprotein and a.-antitrypsin. Clin Chim Acta. 125:311 (1982).PubMedCrossRefGoogle Scholar
  94. 94.
    H. Lewinsky, U. Gafter, J. Levi, and D. Allalouf, Neuramidase-like activity in sera of uremic anemic patients, Nephron. 37:35 (1984).CrossRefGoogle Scholar
  95. 95.
    J.S. Shannon, T.R.J. Lappin, G.E. Elder, G.M. Roberts, M.G. McGeown, and J.M. Bridges, Increased plasma glycosidase and protease activity in uraemia: possible role in the aetiology of the anaemia of chronic renal failure. Clin Chim Acta. 153:203 (1985).PubMedCrossRefGoogle Scholar
  96. 96.
    J.I. Kurland, A. Meyors, and M.A.S. Moore, Synthesis and release of erythroid colony-and burst-potentiating activities by purified populations of murine peritoneal macrophages. J Exp Med. 151:839 (1980).PubMedCrossRefGoogle Scholar
  97. 97.
    J.N. Rich, W. Heit, and B. Kubanek, An erythropoietic stimulating factor similar to erythropoietin released by macrophages after treatment with silica. Blut 4: 297 (1980).Google Scholar
  98. 98.
    K. Jacobs, C. Shoemaker, R. Rudersdorf, S.D. Neill, R.J. Kaufman, A. Mufson, J. Seehra, S.S. Jones, R. Hewich, E.F. Fritsch, M. Kawakita, T. Shimizu, and T. Miyake, Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806 (1985).PubMedCrossRefGoogle Scholar
  99. 99.
    J.W. Eschbach, J. Mladenovic, J. F. Garcia, P. W. Wahl, and J. W. Adamson, The anemia of chronic renal failure sheep. Response to erythropoietin-rich plasma in vivo. J Clin Invest. 74:434 (1984).PubMedCrossRefGoogle Scholar
  100. 100.
    J. Mladenovic, J.W. Eschbach, J.R. Koup, J.F. Garcia, and J.W. Adamson, Erythropoietin kinetics in normal and uremic sheep. J Lab Clin Med. 195:659 (1985).Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Tor-Erik Widerøe
    • 1
  1. 1.Department of NephrologyUniversity hospital of TrondheimNorway

Personalised recommendations